Can Sotorasib be used in combination with immunological drugs?

Sotorasib is a KRAS G12C inhibitor, mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations. It exerts anti-cancer effects by targeting and inhibiting the KRAS G12C mutated protein and blocking the growth signaling pathways of tumor cells. Since the KRAS mutation has long been considered an "undruggable" target, the launch of sotoraxib is considered a major breakthrough and has also triggered research and exploration into its use in combination with other therapies.

Currently, the potential of sotoraxib in combination with immune checkpoint inhibitors, such asPD-1/PD-L1 antibodies, is being actively evaluated in clinical trials. Researchers hope to enhance the anti-tumor effect through combined immunotherapy and improve the overall response rate and progression-free survival of patients. However, because these two types of drugs may have immune-related toxic reactions, the safety of combination therapy in the early research phase still needs to be carefully evaluated. Some patients have experienced side effects such as abnormal liver function after combined use.

Nonetheless, preliminary clinical data have shown that combination therapy with sotoraxib and immunological drugs shows good efficacy in some patients, especially when immunotherapy alone is ineffective, and is expected to provide new treatment options for patients. At present, this type of combination therapy has not yet become a standard treatment plan and is still in the clinical research stage. Doctors will carefully decide whether to try combination therapy based on individual conditions.

In general, the combined use of sotoraxib and immune drugs has certain prospects, but more clinical trials are still needed to verify its efficacy and safety. Until then, patients should follow their doctor's advice, and it is not recommended to try combined medications on their own. As research progresses in the future, this combination is expected to become a new treatment strategy for some patients with KRAS G12C mutations.

Reference materials:https://www.lumakras.com/